4.8 Article

Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.0308757101

Keywords

-

Funding

  1. NCI NIH HHS [CA92625, P01 CA092625] Funding Source: Medline
  2. NHLBI NIH HHS [K08 HL067580, K08 HL67580-02] Funding Source: Medline
  3. NIAID NIH HHS [AI35714, P01 AI035714] Funding Source: Medline

Ask authors/readers for more resources

The nonhomologous DNA end-joining (NHEJ) pathway contains six known components, including Artemis, a nuclease mutated in a subset of human severe combined immunodeficient patients. Mice doubly deficient for the five previously analyzed NHEJ factors and p53 inevitably develop progenitor B lymphomas harboring der(12)t(12;15) translocations and immunoglobin heavy chain (IgH)/c-myc coamplification mediated by a breakage-fusion-bridge mechanism. In this report, we show that Artemis/p53-deficient mice also succumb reproducibly to progenitor B cell tumors, demonstrating that Artemis is a tumor suppressor in mice. However, the majority of Artemis/p53-deficient tumors lacked der(12)t(12;15) translocations and c-myc amplification and instead coamplified IgH and N-myc through an intra- or interchromosome 12 breakage-fusion-bridge mechanism. We discuss this finding in the context of potential implications for mechanisms that may target IgH locus translocations to particular oncogenes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available